GlassScriptPhysician profile
Lindsey Davis
NPI 1245549435
$8,572.27
in general payments reported to CMS, 2019-2025
36 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,375 · 2022: $1,876 · 2023: $1,647 · 2024: $1,631 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,321.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,038.48 | 2021-2025 | |
| Boston Scientific Corporation | $927.44 | 2021-2025 | Watchman Flx, Watchman, Wavewriter Alpha Prime 16 |
| Janssen Pharmaceuticals, INC | $894.08 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $645.75 | 2021-2025 | Lifevest |
| Abbott Laboratories | $559.23 | 2021-2024 | Mitraclip, Cardiomems, Aveir |
| Astrazeneca Pharmaceuticals LP | $486.45 | 2021-2025 | Farxiga, Andexxa, Wainua |
| Abiomed | $415.69 | 2024-2025 | Impella |
| Pfizer INC. | $409.57 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $393.20 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.55 | 2021-2025 | Jardiance |
| Philips North America LLC | $361.80 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Merck Sharp & Dohme LLC | $336.30 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $245.09 | 2021-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $234.33 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Alnylam Pharmaceuticals INC. | $199.80 | 2023-2025 | Onpattro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $150.50 | 2021-2022 | |
| Novo Nordisk INC | $130.15 | 2024-2025 | Wegovy |
| Inari Medical, INC. | $124.18 | 2022 | |
| Cardiva Medical, INC. | $82.38 | 2025 | Savvywire, Optowire, Cardiva Vascade Mvp Vvcs 6-12f |
| Kestra Medical Technology Services, INC. | $72.63 | 2023-2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $59.56 | 2022-2025 | |
| Esperion Therapeutics, INC. | $54.59 | 2021-2022 | |
| Teleflex LLC | $53.34 | 2021-2023 | Langston, Vascband |
| Convatec INC. | $50.52 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $37.97 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $37.86 | 2024 | Arcalyst |
| Endotronix, INC. | $35.51 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Vital Connect, INC | $26.13 | 2025 | Vitalpatch Rtm |
| Actelion Pharmaceuticals US, INC. | $23.94 | 2023 | Uptravi, Opsumit |
| Cvrx, INC. | $22.66 | 2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $19.13 | 2022 | |
| Bard Peripheral Vascular, INC. | $16.96 | 2024 | Rotarexs 6 F X 135 Cm |
| Atricure, INC. | $15.86 | 2024 | |
| Medicomp INC | $15.64 | 2023 | Telepatch Cardiac Monitor |
| W. L. Gore & Associates, INC. | $14.83 | 2024 | Gore Cardioform Septal Occluder |
| Biotronik INC. | $14.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.